The ad goes on to tout Hims & Hers' weight loss drugs as less expensive alternatives to medications like Ozempic and Wegovy, ...

Hims & Hers has shown impressive revenue growth, accelerating from 46% to 77%. Read why I downgrade HIMS stock from buy to ...

Hims & Hers Health (NYSE: HIMS) is surging today. The stock is up 19%, and this is part of a broader 482.5% rally in the past year that has carried this telehealth company to nosebleed levels. Here’s ...

When it comes to achieving healthy body weight, some men might look to what’s average and use that as their goal. For ...

Hims has a great deal of meme potential, which could benefit the company by effectively acting as free advertising. Read more ...

Hims and Hers are being scrutinized after running a Super Bowl ad, claiming to be a less expensive alternative to Ozempic and ...

Hims & Hers Health, Inc. (HIMS) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...

Novo Nordisk ( NVO -2.98%) stock is in a funk. Shares of the GLP-1 diet drug manufacturer have been sliding all week long, ...

U.K.-based ad agency DAIVID said Pfizer had a strong, positive message with its ad and scored high with intense positive emotions. The commercial was also a top performer with spikes in positive ...

Hims & Hers offers a copycat of the blockbuster ... that sell compounded drugs that may disappear from the market without much notice. That’s a tough spot to be in. Clinical data show that ...

Compounded semaglutide is legal, but it's not regulated in the same way as medications like Ozempic and Wegovy.

Though the big game has long been hallowed ground for some of the most entertaining and memorable commercials, they often don ...